RXRX - Recursion Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$8.25
DETAILS
HIGH:
$11.00
LOW:
$5.50
MEDIAN:
$8.25
CONSENSUS:
$8.25
UPSIDE:
174.09%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Revenue | 74.7 | 58.8 | 43.9 | 39.7 | 10 | 3.4 | 1.7 |
| Cost of Revenue | 121.0 | 45.2 | 42.6 | 48.3 | 0 | 0 | 45.8 |
| Gross Profit | (46.3) | 13.6 | 1.3 | (8.6) | 10 | 3.4 | (44.1) |
| Operating Expenses | |||||||
| R&D Expenses | 425.3 | 314.4 | 241.2 | 155.7 | 135.3 | 63.3 | 45.8 |
| SG&A Expenses | 176.6 | 178.2 | 110.8 | 81.6 | 57.7 | 25.3 | 19.0 |
| Other Expenses | 0 | 0 | (0.7) | (0.2) | (0.2) | (0.5) | (0.6) |
| Operating Expenses | 601.9 | 492.6 | 351.3 | 237.1 | 192.8 | 88.0 | 64.2 |
| Operating Income | |||||||
| Operating Income | (648.1) | (479.0) | (350.1) | (245.7) | (182.8) | (84.6) | (62.4) |
| Interest Expense | 1.8 | 1.6 | 0.1 | 0.1 | 3.0 | 1.4 | 0.6 |
| Interest Income | 22.8 | 15.8 | 19.1 | 6.3 | 0.1 | 0.3 | 1.7 |
| Profitability | |||||||
| EBITDA | (559.4) | (426.7) | (307.6) | (227.7) | (175.1) | (81.7) | (58.3) |
| EBIT | (643.1) | (463.2) | (332.0) | (239.4) | (183.5) | (85.6) | (61.9) |
| Income Before Tax | (644.9) | (464.8) | (332.1) | (239.5) | (186.5) | (87.0) | (61.9) |
| Income Tax Expense | (0.1) | (1.1) | (4.1) | 0 | 0 | 0 | 0 |
| Net Income | (644.8) | (463.7) | (328.1) | (239.5) | (186.5) | (87.0) | (62.5) |
| Per Share Data | |||||||
| EPS (Basic) | -1.44 | -1.69 | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| EPS (Diluted) | -1.44 | -1.69 | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| Shares Outstanding | 447.4 | 274.2 | 207.9 | 175.5 | 170.3 | 165.8 | 165.8 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Current Assets | |||||||
| Cash & Cash Equivalents | 743.3 | 594.4 | 391.6 | 549.9 | 285.1 | 262.1 | 69.9 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 231.4 | 0 | 0 |
| Net Receivables | 24.6 | 49.2 | 3.1 | 2.8 | 9.1 | 0.2 | 0.2 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 44.9 | 70.8 | 43.5 | 17.1 | 9.1 | 4.2 | 6.4 |
| Total Current Assets | 812.8 | 714.3 | 438.1 | 569.8 | 534.7 | 266.4 | 76.4 |
| Non-Current Assets | |||||||
| Property, Plant & Equipment | 169.5 | 233.2 | 120.2 | 121.4 | 64.7 | 26.0 | 24.4 |
| Goodwill | 162.2 | 148.9 | 52.1 | 0.8 | 0.8 | 0.8 | 0 |
| Intangible Assets | 309.9 | 335.9 | 36.4 | 1.3 | 1.4 | 1.7 | 0 |
| Long-Term Investments | 0 | 5.6 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 18.8 | 8.8 | 6.9 | 7.9 | 8.7 | 3.7 | 0.7 |
| Total Non-Current Assets | 661.3 | 734.3 | 215.6 | 131.5 | 75.6 | 32.1 | 25.0 |
| Total Assets | 1,474.1 | 1,448.6 | 653.7 | 701.3 | 610.3 | 298.6 | 101.4 |
| Current Liabilities | |||||||
| Account Payables | 18.1 | 21.6 | 4.0 | 4.6 | 2.8 | 1.1 | 1.3 |
| Short-Term Debt | 21.8 | 22.2 | 0.0 | 0.1 | 0.1 | 1.1 | 0.1 |
| Deferred Revenue | 37.6 | 61.8 | 36.4 | 56.7 | 10 | 10 | 0 |
| Other Current Liabilities | 70.2 | 81.9 | 23.7 | 20.4 | 11.7 | 3.1 | 1.7 |
| Total Current Liabilities | 147.7 | 187.5 | 93.2 | 100.3 | 46.7 | 23.1 | 6.7 |
| Non-Current Liabilities | |||||||
| Long-Term Debt | 56.2 | 19.0 | 1.1 | 0.5 | 0.6 | 11.4 | 12.4 |
| Deferred Tax Liabilities | 23.3 | 16.6 | 1.3 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 116.1 | 4.7 | 0 | 0 | 4.1 | 451.0 | 203.4 |
| Total Non-Current Liabilities | 195.6 | 226.3 | 97.1 | 115.2 | 20.7 | 481.8 | 219.0 |
| Total Liabilities | 343.3 | 413.8 | 190.3 | 215.5 | 67.4 | 504.9 | 225.7 |
| Stockholders' Equity | |||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 |
| Retained Earnings | (2,076.0) | (1,431.3) | (967.6) | (639.6) | (400.1) | (213.6) | (126.6) |
| Accumulated Other Comprehensive Income | 36.7 | (7.6) | 0 | 0 | (0.1) | 0 | 0 |
| Total Stockholders' Equity | 1,130.9 | 1,034.8 | 463.4 | 485.8 | 542.9 | (206.3) | (124.3) |
| Total Liabilities & Equity | 1,474.1 | 1,448.6 | 653.7 | 701.3 | 610.3 | 298.6 | 101.4 |
| Debt Metrics | |||||||
| Total Debt | 78.0 | 108.5 | 50.7 | 51.0 | 11.5 | 15.7 | 16.2 |
| Net Debt | (665.3) | (485.9) | (340.9) | (498.9) | (273.6) | (246.5) | (53.7) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | (644.8) | (463.7) | (328.1) | (239.5) | (186.5) | (87.0) | (61.9) |
| Depreciation & Amortization | 83.7 | 36.5 | 24.4 | 11.8 | 8.4 | 3.9 | 2.5 |
| Stock-Based Compensation | 111.2 | 81.7 | 53.5 | 27.9 | 14.8 | 4.3 | 1.4 |
| Change in Working Capital | 13.7 | (38.0) | (50.3) | 104.9 | (0.3) | 30.8 | 0.4 |
| Other Non-Cash Items | 64.3 | 24.3 | 12.6 | 11.4 | 4.1 | 2.5 | 0.6 |
| Operating Cash Flow | (371.8) | (359.2) | (287.8) | (83.5) | (158.6) | (45.4) | (57.0) |
| Investing Activities | |||||||
| Capital Expenditure | (6.5) | (13.7) | (12.0) | (37.4) | (39.8) | (6.7) | (3.9) |
| Acquisitions | 0 | 277.1 | 1.8 | 0 | 231.9 | (2.6) | 0 |
| Purchases of Investments | (3.8) | 0 | 0 | 0 | (301.1) | 0 | 0 |
| Sales/Maturities of Investments | 0 | 0 | 0.5 | 230.6 | 69.2 | 0 | 0 |
| Other Investing Activities | (6.6) | (3.4) | (0.6) | (0.3) | (231.9) | (0.3) | 0 |
| Investing Cash Flow | (16.9) | 260.1 | (10.2) | 193.2 | (271.7) | (8.7) | (3.9) |
| Financing Activities | |||||||
| Net Debt Issuance | (8.4) | (4.4) | (0.8) | (0.1) | (12.8) | 6.3 | 0.7 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3) | 8.1 | 12.8 | 10.7 | 8.4 | 0.7 | (0.2) |
| Financing Cash Flow | 521.5 | 304.1 | 140.1 | 154.3 | 458.5 | 246.1 | 120.4 |
| Cash Position | |||||||
| Net Change in Cash | 150.9 | 201.6 | (157.7) | 263.8 | 28.2 | 192.0 | 59.5 |
| Cash at Beginning | 603.0 | 401.4 | 559.1 | 295.3 | 267.2 | 75.2 | 15.7 |
| Cash at End | 753.9 | 603.0 | 401.4 | 559.1 | 295.3 | 267.2 | 75.2 |
| Free Cash Flow | (378.3) | (372.9) | (300.3) | (120.9) | (198.4) | (52.1) | (61.0) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 74.7 | 58.8 | 43.9 | 39.7 | 10 | 3.4 | 1.7 |
| Gross Profit | (46.3) | 13.6 | 1.3 | (8.6) | 10 | 3.4 | (44.1) |
| Operating Income | (648.1) | (479.0) | (350.1) | (245.7) | (182.8) | (84.6) | (62.4) |
| Net Income | (644.8) | (463.7) | (328.1) | (239.5) | (186.5) | (87.0) | (62.5) |
| EPS (Diluted) | -1.44 | -1.69 | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| Balance Sheet | |||||||
| Cash & Equivalents | 743.3 | 594.4 | 391.6 | 549.9 | 285.1 | 262.1 | 69.9 |
| Total Assets | 1,474.1 | 1,448.6 | 653.7 | 701.3 | 610.3 | 298.6 | 101.4 |
| Total Debt | 78.0 | 108.5 | 50.7 | 51.0 | 11.5 | 15.7 | 16.2 |
| Stockholders' Equity | 1,130.9 | 1,034.8 | 463.4 | 485.8 | 542.9 | (206.3) | (124.3) |
| Cash Flow | |||||||
| Operating Cash Flow | (371.8) | (359.2) | (287.8) | (83.5) | (158.6) | (45.4) | (57.0) |
| Capital Expenditure | (6.5) | (13.7) | (12.0) | (37.4) | (39.8) | (6.7) | (3.9) |
| Free Cash Flow | (378.3) | (372.9) | (300.3) | (120.9) | (198.4) | (52.1) | (61.0) |